MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-25-2026
Dyadic International Operating Income 2011-2026 | DYAI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Dyadic International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.19 M | -5.9 M | -8.23 M | -10.2 M | -14.7 M | -10 M | -9.28 M | -7.59 M | -7.13 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.9 M | -14.7 M | -8.92 M |
Quarterly Operating Income Dyadic International
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.93 M | -1.73 M | - | -203 K | -2.04 M | -2.13 M | - | -1.72 M | -2.29 M | -2.05 M | - | -1.86 M | -3.32 M | -2.74 M | - | -3.32 M | -3.87 M | -3.32 B | - | -2.58 M | -2.8 M | -2.38 M | - | -1.94 M | -2.96 M | -2.44 M | - | -1.78 M | -1.82 M | -2.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -203 K | -3.32 B | -147 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
-170 M | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
VistaGen Therapeutics
VTGN
|
-56 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Avid Bioservices
CDMO
|
-18.7 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-57.1 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-121 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-130 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-15.9 M | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
-189 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
-72.1 M | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Zymeworks
ZYME
|
-216 M | $ 24.18 | -2.07 % | $ 1.25 B | Canada |
 |
AbbVie
ABBV
|
15.1 B | $ 209.4 | -0.83 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Altimmune
ALT
|
-94.5 M | $ 3.02 | -5.63 % | $ 266 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.21 | -6.2 % | $ 309 M | Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.6 | -2.8 % | $ 16.3 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-38.2 M | $ 4.29 | -3.6 % | $ 822 M | Canada |